Marco Mielcarek, MD

Associate Member
Clinical Research Division
Associate Professor, Department of Medicine
University of Washington
Medical Director, Adult Blood and Marrow Transplantation
Fred Hutch and Seattle Cancer Care Alliance

Education:

Freie Universität Berlin, School of Medicine, Germany
M.D.; Freie Universität Berlin
PhD: Freie Universität Berlin, 1987
 

Research Focus:

Preventing graft-versus-host disease (GVHD) after allogeneic stem cell transplantation:

  • clinical trials of donor or recipient statin treatment for GVHD-prevention
  • laboratory studies aimed at identifying mechanisms of statin-mediated immunosuppression
  • pre-clinical studies in the canine GVHD model
  • clinical trial of posttransplant cyclophosphamide for prevention of chronic GVHD after PBSC transplantation

Reducing the toxicity of GVHD treatment:

  • clinical trial of establishing safety and efficacy of low-dose glucocorticoids for treatment of acute GVHD

Establishing safety and efficacy of bortezomib maintenance therapy after allografting for patients with multiple myeloma

Clinical Expertise:

Blood and bone marrow stem cell transplantation for hematologic cancers. Graft-versus-host disease (GVHD).

Current Studies:

Dr. Mielcarek’s research is aimed at preventing graft-versus-host disease (GVHD) and making treatments for this immune-triggered inflammatory syndrome more tolerable. Over the past decade, advances in donor selection, typing technology, supportive care, and preventive drugs have all helped to reduce the number of patients who suffer the dire consequences of GVHD. But 10 to 15 percent of patients with matched grafts still develop severe acute GVHD (grades III or IV). And half end up with the late-developing chronic GVHD. Dr. Mielcarek and his research colleagues are testing whether statin treatment of stem cell donors has the potential to prevent GVHD in recipients. Animal studies and retrospective studies show that these widely used cholesterol-lowering agents appear to weaken T-cell function in a way that reduces GVHD.

Dr. Mielcarek’s research is aimed at preventing graft-versus-host disease (GVHD) and making treatments for this immune-triggered inflammatory syndrome more tolerable. Over the past decade, advances in donor selection, typing technology, supportive care, and preventive drugs have all helped to reduce the number of patients who suffer the dire consequences of GVHD. But 10 to 15 percent of patients with matched grafts still develop severe acute GVHD (grades III or IV). And half end up with the late-developing chronic GVHD. Dr. Mielcarek and his research colleagues are testing whether statin treatment of stem cell donors has the potential to prevent GVHD in recipients. Animal studies and retrospective studies show that these widely used cholesterol-lowering agents appear to weaken T-cell function in a way that reduces GVHD.



file

Contact Information

Phone
(206) 667-2827
Fax
(206) 667-6124
Email
Additional contact

Mail Stop: D1-100

Fred Hutchinson Cancer Research Center is a world leader in research to prevent, detect and treat cancer and other life-threatening diseases.